NAD+ IV Infusions

Clarus Health is the Bay Area's only BR+ certified Niagen provider, offering both standard NAD+ IV infusions and next-generation Niagen (NMN/NR-based) intravenous protocols. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy production, DNA repair, and the activity of sirtuins — proteins associated with longevity and metabolic regulation. IV delivery achieves substantially higher plasma and cellular NAD+ levels than oral supplementation. Clarus offers a structured initial infusion series followed by periodic maintenance boosters, with dosing from 500mg to 1,000mg per session. Protocols are personalised to each client's health status, goals, and genomic profile.

Clarus Health occupies a distinctive position in the San Francisco NAD+ therapy landscape as the Bay Area's sole BR+ certified Niagen provider. Niagen is the commercial form of nicotinamide riboside (NR), a NAD+ precursor developed by ChromaDex that has been the subject of multiple human clinical trials examining bioavailability and cellular NAD+ elevation. BR+ certification indicates adherence to a specific purity and protocol standard established for clinical Niagen use, distinguishing Clarus's NAD+ programme from clinics using commodity NAD+ compounds. NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme found in every cell in the body, where it serves two fundamental roles: as an electron carrier in the mitochondrial electron transport chain (driving ATP synthesis) and as a substrate for a class of enzymes including sirtuins (SIRT1–SIRT7), poly-ADP ribose polymerases (PARPs), and CD38 that regulate DNA repair, inflammation, circadian rhythm, and cellular stress responses. NAD+ levels decline with age and are further depleted by metabolic stress, alcohol consumption, inflammatory conditions, and certain nutrient deficiencies — a decline associated with reduced mitochondrial efficiency, impaired DNA repair capacity, and accelerated cellular senescence. Intravenous NAD+ delivery achieves plasma concentrations substantially higher than what is attainable through oral NR or NMN supplementation, where intestinal absorption and hepatic first-pass metabolism limit systemic exposure. Clarus offers NAD+ infusions across a dose range from 500mg to 1,000mg per session. The initial series protocol — multiple infusions delivered over one to two weeks — is recommended for clients who are new to NAD+ therapy, as it establishes elevated NAD+ pools before transitioning to periodic maintenance boosters. The LDK complex add-on at the 1,000mg tier represents an additional stack of co-factors selected to support NAD+ utilisation pathways. At Clarus Health in San Francisco, NAD+ infusions are also available as an adjunct to the clinic's ketamine infusion programme, where the combination may support neuroplasticity, mitochondrial recovery, and mood stability during the post-infusion integration period. All NAD+ protocols are supervised by the Clarus physician team and can be integrated with the clinic's comprehensive biomarker testing to track objective markers of cellular energy metabolism over time.